DIAGNOS (ADK) Stock Price, News & Analysis

Company Overview

DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.

Key Stats

• Today's Range: C$0.27 to C$0.29
• 50-Day Range: C$0.26 to C$0.38
• 52-Week Range: C$0.23 to C$0.57
• Volume: 159,800 shs
• Average Volume: 92,571 shs
• Market Capitalization: C$23.21 million
• P/E Ratio: N/A
• Dividend Yield: 0.29%
• Price Target: C$1.50
• Consensus Rating: Strong Buy

DIAGNOS Stock Analysis - MarketRank™

DIAGNOS scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

DIAGNOS has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

DIAGNOS has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of DIAGNOS is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DIAGNOS is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ADK.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

DIAGNOS has a dividend yield of 0.29%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

DIAGNOS does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ADK.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for DIAGNOS this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DIAGNOS insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.81% of the stock of DIAGNOS is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.01% of the stock of DIAGNOS is held by institutions.

ADK Stock Analysis - Frequently Asked Questions

How have ADK shares performed this year?

DIAGNOS's stock was trading at C$0.41 at the start of the year. Since then, ADK stock has decreased by 29.6% and is now trading at C$0.29.
View the best growth stocks for 2024 here.

How do I buy shares of DIAGNOS?

Shares of ADK stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of DIAGNOS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DIAGNOS investors own include DIAGNOS (DGNOF), Facedrive (FDVRF), New Found Gold (NFGC), Ackroo (AKR), BeWhere (BEW), BlueRush (BTV) and Grande West Transportation Group (BUS).

Company Calendar

• Today: 11/23/2024
• Next Earnings (Estimated): 11/26/2024

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: CVE:ADK
• CUSIP: N/A
• CIK: N/A
• Web: www.diagnos.ca
• Phone: +1-450-6788882
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$1.50
• High Stock Price Target: C$1.50
• Low Stock Price Target: C$1.50
• Potential Upside/Downside: +426.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-3,090,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -134.33%

Debt

• Debt-to-Equity Ratio: 245.28
• Current Ratio: 0.39
• Quick Ratio: 0.68

Sales & Book Value

• Annual Sales: C$577,486.00
• Price / Sales: 40.19
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 60.00
• Book Value: C($0.03) per share
• Price / Book: -9.50

Miscellaneous

• Outstanding Shares: 81,440,000
• Free Float: N/A
• Market Cap: C$23.21 million
• Optionable: Not Optionable
• Beta: -0.44